Kiran Gajurel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kiran Gajurel has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Reshika Dhakal
Department of Internal Medicine Carver College of Medicine University of Iowa Iowa City Iowa
4 shared publicationsStan Deresinski
Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
3 shared publications- Stan Deresinski
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 94305, USA
3 shared publications - Reshika Dhakal
Labcorp, Indianapolis, IN 46214, USA
2 shared publications Alia K. Boland
Atrium Health Carolinas Medical Center
1 shared publication- Alynna J. Wiley
Department of Surgery, Carolinas Medical Center, Advocate Health, NC, USA
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6  (1) , e312
Opportunities for antiviral stewardship: a single-center evaluation of maribavir use in solid organ transplant recipients
Objective: Maribavir is a novel antiviral for resistant or refractory (R/R) CMV infection with a favorable safety profile. This report describes institutional use of maribavir in solid organ transplant (SOT) recipients with CMV infection to better understand antiviral stewardship opportunities. Design: Retrospective case series. Setting: Tertiary referral center. Patients/Methods: This was a single center case series of adult SOT recipients who received maribavir for treatment of R/R CMV infection. The primary outcome was treatment success by 8 weeks. Treatment failure, including development of maribavir resistance, and CMV recurrence were also assessed. Results: Maribavir was used for treatment of 23 episodes of CMV infection in 20 SOT recipients. Treatment success was achieved in 14 (60.9%) episodes in unique patients, with 5/14 patients (35.7%) experiencing CMV recurrence within four weeks of maribavir discontinuation. Treatment failure occurred in 9 (39.1%) of 23 treatment courses, with 6/20 (30%) patients developing treatment-emergent maribavir resistance. Conclusion: Maribavir was a viable option for the management of R/R CMV infection in our real-world single center cohort, as success mirrored that seen in other studies. However, there was a clinically significant portion of patients who failed maribavir or had recurrent CMV. Continued multi-center analysis of maribavir timing, secondary prophylaxis, and patient characteristics that may predict success are warranted to help improve the stewardship of this valuable antiviral.
- 5 October 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6  (1) , e312
Open AccessOpportunities for antiviral stewardship: a single-center evaluation of maribavir use in solid organ transplant recipients
Objective: Maribavir is a novel antiviral for resistant or refractory (R/R) CMV infection with a favorable safety profile. This report describes institutional use of maribavir in solid organ transplant (SOT) recipients with CMV infection to better understand antiviral stewardship opportunities. Design: Retrospective case series. Setting: Tertiary referral center. Patients/Methods: This was a single center case series of adult SOT recipients who received maribavir for treatment of R/R CMV infection. The primary outcome was treatment success by 8 weeks. Treatment failure, including development of maribavir resistance, and CMV recurrence were also assessed. Results: Maribavir was used for treatment of 23 episodes of CMV infection in 20 SOT recipients. Treatment success was achieved in 14 (60.9%) episodes in unique patients, with 5/14 patients (35.7%) experiencing CMV recurrence within four weeks of maribavir discontinuation. Treatment failure occurred in 9 (39.1%) of 23 treatment courses, with 6/20 (30%) patients developing treatment-emergent maribavir resistance. Conclusion: Maribavir was a viable option for the management of R/R CMV infection in our real-world single center cohort, as success mirrored that seen in other studies. However, there was a clinically significant portion of patients who failed maribavir or had recurrent CMV. Continued multi-center analysis of maribavir timing, secondary prophylaxis, and patient characteristics that may predict success are warranted to help improve the stewardship of this valuable antiviral.
- 17 December 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26  (4) , 896-899
Donor-derived blastomycosis
- 17 December 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26  (4) , 896-899
Donor-derived blastomycosis
- 25 November 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28  (1) , e70143
Angioinvasive Hepatic Mucormycosis in a Heart Transplant Recipient
- 25 November 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28  (1) , e70143
Angioinvasive Hepatic Mucormycosis in a Heart Transplant Recipient
- Open Access
Correction: Gajurel et al. Arbovirus in Solid Organ Transplants: A Narrative Review of the Literature. Viruses 2024, 16, 1778
In the original publication, there was a mistake in Table 1 as published
Open AccessCorrection: Gajurel et al. Arbovirus in Solid Organ Transplants: A Narrative Review of the Literature. Viruses 2024, 16, 1778
In the original publication, there was a mistake in Table 1 as published
- Open Access
Arbovirus in Solid Organ Transplants: A Narrative Review of the Literature
The incidence of arbovirus infections has increased in recent decades. Other than dengue, chikungunya, and West Nile viruses, the data on arbovirus in solid organ transplant (SOT) are limited to case reports, and infections in renal transplant recipients account for most of the reported cases. Dengue and West Nile infections seem to be more severe with higher mortality in SOT patients than in the general population. Acute kidney injury is more frequent in patients with dengue and chikungunya although persistent arthralgia with the latter is less frequent. There is no clear relationship between arboviral infection and acute cellular rejection. Pre-transplant screening of donors should be implemented during increased arboviral activity but, despite donor screening and negative donor nucleic acid amplification test (NAT), donor derived infection can occur. NAT may be transiently positive. IgM tests lack specificity, and neutralizing antibody assays are more specific but not readily available. Other tests, such as immunohistochemistry, antigen tests, PCR, metagenomic assays, and viral culture, can also be performed. There are a few vaccines available against some arboviruses, but live vaccines should be avoided. Treatment is largely supportive. More data on arboviral infection in SOT are needed to understand its epidemiology and clinical course.
Open AccessArbovirus in Solid Organ Transplants: A Narrative Review of the Literature
The incidence of arbovirus infections has increased in recent decades. Other than dengue, chikungunya, and West Nile viruses, the data on arbovirus in solid organ transplant (SOT) are limited to case reports, and infections in renal transplant recipients account for most of the reported cases. Dengue and West Nile infections seem to be more severe with higher mortality in SOT patients than in the general population. Acute kidney injury is more frequent in patients with dengue and chikungunya although persistent arthralgia with the latter is less frequent. There is no clear relationship between arboviral infection and acute cellular rejection. Pre-transplant screening of donors should be implemented during increased arboviral activity but, despite donor screening and negative donor nucleic acid amplification test (NAT), donor derived infection can occur. NAT may be transiently positive. IgM tests lack specificity, and neutralizing antibody assays are more specific but not readily available. Other tests, such as immunohistochemistry, antigen tests, PCR, metagenomic assays, and viral culture, can also be performed. There are a few vaccines available against some arboviruses, but live vaccines should be avoided. Treatment is largely supportive. More data on arboviral infection in SOT are needed to understand its epidemiology and clinical course.
- Open Access
- 28 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9  (10) , e1544
Vaccination in Kidney Transplant Candidates
Background: Kidney transplant (KT) candidates have historically low immunization rates against recommended vaccines. A retrospective single-center study of contemporary KT candidates was conducted to assess vaccination rates and vaccine uptake. Methods: All KT candidates ≥18 y evaluated between January 1, 2020, and December 31, 2020, were retrospectively reviewed for history of prior vaccination against tetanus, diphtheria, and pertussis; 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; and recombinant zoster vaccine. Positive hepatitis A IgG total, hepatitis B surface antibody, measles, mumps, rubella, and varicella IgG were assessed as surrogate markers of immunity. Vaccine uptake among vaccine-eligible candidates was also assessed. Results: Among 150 KT candidates, the rate of prior vaccination against tetanus, diphtheria, and pertussis; 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; and recombinant zoster vaccine (latter among patients ≥50 y) was found to be as low as 11%. Hepatitis A IgG total, hepatitis B surface antibody, measles, mumps, rubella, and varicella IgG seropositivity rates were 30%, 66%, 88%, 78%, 90%, and 96%, respectively. Only 7 (5%) of 150 patients had complete immunization or seropositivity. Five (3%) of 143 vaccine-eligible patients declined vaccination. Hepatitis A vaccine declination was relatively common with 15 (16%) of 94 vaccine-eligible patients declining it. Conclusions: KT candidates have low baseline rates of prior immunization/seropositivity against most recommended vaccines. Overall vaccine uptake among eligible candidates was high.
- 28 September 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9  (10) , e1544
Open AccessVaccination in Kidney Transplant Candidates
Background: Kidney transplant (KT) candidates have historically low immunization rates against recommended vaccines. A retrospective single-center study of contemporary KT candidates was conducted to assess vaccination rates and vaccine uptake. Methods: All KT candidates ≥18 y evaluated between January 1, 2020, and December 31, 2020, were retrospectively reviewed for history of prior vaccination against tetanus, diphtheria, and pertussis; 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; and recombinant zoster vaccine. Positive hepatitis A IgG total, hepatitis B surface antibody, measles, mumps, rubella, and varicella IgG were assessed as surrogate markers of immunity. Vaccine uptake among vaccine-eligible candidates was also assessed. Results: Among 150 KT candidates, the rate of prior vaccination against tetanus, diphtheria, and pertussis; 13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; and recombinant zoster vaccine (latter among patients ≥50 y) was found to be as low as 11%. Hepatitis A IgG total, hepatitis B surface antibody, measles, mumps, rubella, and varicella IgG seropositivity rates were 30%, 66%, 88%, 78%, 90%, and 96%, respectively. Only 7 (5%) of 150 patients had complete immunization or seropositivity. Five (3%) of 143 vaccine-eligible patients declined vaccination. Hepatitis A vaccine declination was relatively common with 15 (16%) of 94 vaccine-eligible patients declining it. Conclusions: KT candidates have low baseline rates of prior immunization/seropositivity against most recommended vaccines. Overall vaccine uptake among eligible candidates was high.
- Open Access
- 1 November 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1  (9)
Brownish-Yellow Layering on Skin—an Unusual Manifestation of Cutaneous Aspergillosis in a Heart Transplant Recipient
An unusual cutaneous manifestation of aspergillosis in an immunocompromised patient in which Aspergillus terreus grew on the necrotic skin, creating a brownish-yellow layer of fungal growth, is rep...
- 1 November 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1  (9)
Open AccessBrownish-Yellow Layering on Skin—an Unusual Manifestation of Cutaneous Aspergillosis in a Heart Transplant Recipient
An unusual cutaneous manifestation of aspergillosis in an immunocompromised patient in which Aspergillus terreus grew on the necrotic skin, creating a brownish-yellow layer of fungal growth, is rep...
- Open Access
- 1 March 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1  (1)
Disseminated Cutaneous Mycobacterium marinum Infection
Infection with Mycobacterium marinum has been associated with inhibitors of tumor necrosis factor alpha but rarely reported in patients given golimubab. We report an unusual case of disseminated cu...
- 1 March 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1  (1)
Open AccessDisseminated Cutaneous Mycobacterium marinum Infection
Infection with Mycobacterium marinum has been associated with inhibitors of tumor necrosis factor alpha but rarely reported in patients given golimubab. We report an unusual case of disseminated cu...
- 1 March 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74  (5) , 933-937
A Healthy Adult With Tibial Swelling and Pain
- 1 March 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74  (5) , 933-937
A Healthy Adult With Tibial Swelling and Pain
- Open Access
- 21 February 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8  (3) , e1291
Unusual Presentation of Disseminated Mycobacterium kansasii Infection in Renal Transplant Recipients and Rapid Diagnosis Using Plasma Microbial Cell-free DNA Next-generation Sequencing
- 21 February 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8  (3) , e1291
Open AccessUnusual Presentation of Disseminated Mycobacterium kansasii Infection in Renal Transplant Recipients and Rapid Diagnosis Using Plasma Microbial Cell-free DNA Next-generation Sequencing